Previous 10 | Next 10 |
Gainers: Biofrontera (NASDAQ:BFRI) +26%, Gemini Therapeutics (NASDAQ:GMTX) +19%, Vir Biotechnology (NASDAQ:VIR) +14%, Mesoblast (NASDAQ:MESO) +14%, Tandem Diabetes Care (NASDAQ:TNDM) +10% Losers: Atai Life Sciences (NASDAQ:ATAI) -24%, Alzamend...
Chinese biotech companies listed on U.S. financial markets are trading lower in the pre-market amid reports that the Biden administration is weighing tougher sanctions on China’s largest chipmaker, Semiconductor Manufacturing International Corp. (OTCQX:SMICY). A meeting scheduled for T...
Legend Biotech (NASDAQ:LEGN) trades 2.4% down after hours on announcing its intention to offer and sell $300M of ADSs, each representing two ordinary shares, in an underwritten public offering. Underwriters granted 30-day option to purchase up to an additional $45M of ADSs sold...
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it intends to offer and sell $300.0 mil...
Updated CARTITUDE-1 data presented at ASH 2021 demonstrate a 98 percent overall response rate and 83 percent stringent complete response rate after nearly two years of follow-up CARTITUDE-1 study data also reported 2-year progression-free survival and overall survival rates we...
Legend Biotech (LEGN +10.5%) has gained more than a tenth in value, recording the biggest intraday gain since May after announcing the submission of the marketing application in Japan for its chimeric antigen receptor (CAR)-T cell therapy cilta-cel in multiple myeloma. With the New Drug Appli...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that it will host a hybrid event featuring key opinion leaders (KOLs) in multiple myeloma on Monday, December 13 at 8p...
Legend Biotech requests that their press release NewsItemId: 20211206005107 “Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janss...
Submission based on data from pivotal CARTITUDE-1 trial Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese Mini...
Legend Biotech (NASDAQ:LEGN): Q3 GAAP EPS of -$0.43 misses by $0.08. Revenue of $16.82M (+43.3% Y/Y) beats by $8.99M. Shares +5.88% PM. Press Release For further details see: Legend Biotech EPS misses by $0.08, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...